COMMUNIQUÉS West-GlobeNewswire

Myriad to Announce Fiscal Second-Quarter 2018 Financial Results on February 6, 2018

25/01/2018 - 13:05

SALT LAKE CITY, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN ) today announced that it will hold its fiscal second-quarter 2018 sales and earnings conference call with investors and analysts at [...]

Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical Trial

25/01/2018 - 13:00

Increase in Utrophin Protein Expression Observed Summit Accelerating Preparations for Pivotal Clinical Trial Ezutromid is a Potential Disease-Modifying Treatment for the Entire DMD Patient Population Conference Call [...]

NeuroMetrix Reports Q4 and Full Year 2017 Financial Results

25/01/2018 - 13:00

WALTHAM, Mass., Jan. 25, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO ), today reported financial and business highlights for the quarter ended December 31, 2017. The Company develops and markets novel [...]

Athenex, Inc. Announces Pricing of Offering of Common Stock

25/01/2018 - 13:00

BUFFALO, N.Y., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Athenex (Nasdaq: ATNX ), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer [...]

Eyenovia Announces Pricing of Initial Public Offering

25/01/2018 - 12:30

NEW YORK, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Eyenovia Inc. (“Eyenovia”), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver [...]

Menlo Therapeutics Inc. Announces Pricing of Initial Public Offering of Common Stock

25/01/2018 - 02:47

REDWOOD CITY, Calif., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO ) today announced the pricing of the Company’s initial public offering of 7,000,000 shares of common stock at a public [...]

GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Publication of Landmark Epidiolex® (cannabidiol) Study in The Lancet

25/01/2018 - 00:30

– First well-controlled clinical study of cannabidiol in Lennox-Gastaut syndrome, a rare, severe, form of childhood-onset epilepsy that is difficult to treat – – Pharmaceutical formulation of cannabidiol significantly [...]

REVA Announces First Implant of the Fantom Bioresorbable Scaffold in Italy

24/01/2018 - 23:56

SAN DIEGO, Jan. 24, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced the first implant of the Fantom [...]

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

24/01/2018 - 23:31

BRIDGEWATER, N.J., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced the granting of [...]

PRA Health Sciences to Report Fourth Quarter 2017 Earnings

24/01/2018 - 22:55

RALEIGH, N.C., Jan. 24, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH ) will release its fourth quarter and year end 2017 results after the market closes on Wednesday, February 21, 2018. The Company [...]

Lexington Receives Approval to Commence Clinical Study

24/01/2018 - 15:00

VANCOUVER, British Columbia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce its [...]

Tonix Pharmaceuticals to Present at Noble Capital Markets’ Fourteenth Annual Investor Conference in Fort Lauderdale

24/01/2018 - 22:30

NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP ) (Tonix), announced today that it will present at Noble Capital Markets’ Fourteenth Annual Investor Conference being held [...]

Publication of manuscript related to Phase II trial results for arimoclomol in patients with SOD1 ALS

24/01/2018 - 22:06

Investor news Orphazyme A/S No. 01/2018 Copenhagen, January 24, 2018 – Orphazyme A/S , a Danish biotech company listed on Nasdaq Copenhagen (TICKER: ORPHA.CO), with a late-stage, orphan-drug pipeline, today announced [...]

Iovance Biotherapeutics, Inc. Announces Public Offering of Common Stock

24/01/2018 - 22:02

SAN CARLOS, Calif., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq: IOVA ), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) [...]

Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss

24/01/2018 - 22:01

Novartis enters into a licensing and supply agreement to develop, register and commercialize investigational gene therapy voretigene neparvovec outside the US; Spark Therapeutics retains US rights for LUXTURNA(TM) ( [...]

Novelion Therapeutics Announces Cost Reduction Plans and Capital Structure Review

24/01/2018 - 22:01

VANCOUVER, British Columbia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN ), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare [...]

Albireo Announces Proposed Public Offering of Common Stock

24/01/2018 - 22:01

BOSTON, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO ), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it has commenced an [...]

ConforMIS Announces Proposed Public Offering of Common Stock

24/01/2018 - 22:01

BILLERICA, Mass., Jan. 24, 2018 (GLOBE NEWSWIRE) -- ConforMIS, Inc. (NASDAQ: CFMS ), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell [...]

Iovance Biotherapeutics Announces Preliminary Phase 2 Data for TIL Treatment in Head and Neck and Cervical Cancers

24/01/2018 - 22:01

Three of Eight Evaluable Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with LN-145 Experienced a Confirmed Partial Response One of Two Evaluable Patients with Recurrent, [...]